Q32 Bio QTTB 深 滬
等待開盤 09-23 09:30:00 美东时间
10.57
+0.100
+0.96%
華盛通- 最 高10.99
- 今 開10.60
- 成交量 38.72万股
- 最 低 10.531
- 昨 收 10.47
- 總市值 3.15亿
- 52周最高 23.5699
- 市盈率 靜 4.36
- 換手率 1.30%
- 52周最低 1.905
- 委 比 77.17%
- 總股本 2976.95万
- 歷史最高 572.40
- 量 比 0.69
- 振 幅 4.38%
- 歷史最低 1.345
- 每 手 1
- 風險率 4.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Small-cap stocks with strong momentum grades and triple-digit YTD gains
A group of U.S. small-cap stocks is flashing A+ momentum grades in the latest quantitative screen, with several names posting triple-digit gains year to date. Seeking Alpha's Quant Momentum Grade meas...
09-17 21:55
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
-- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development -- -- Dr. Hershberger is a drug ...
09-14 18:59
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics启动II期临床试验，评估ebribafusp治疗IgA肾病、狼疮性肾炎和C3肾小球病的效果。ebribafusp是一种 investigational 的下一代抗C3d因子H融合蛋白，旨在抑制组织中的补体激活，而不影响血液中的补体系统。试验计划招募最多30名患者，每周一次皮下注射，持续26周，随后是长期扩展研究。主要终点是不良事件的发生率，次要终点包括蛋白尿变化、肾功能和药代动力学。Akebia Therapeutics专注于改善肾脏疾病患者的生活，并在2025年从Q32 Bio获得了ebribafusp的全球权利。初步数据预计在2027年公布。
09-14 12:00
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings
As earnings season ends, investors are turning to updated Quant ratings to see how companies stack up after their latest results. These ratings grade stocks on key metrics like value, growth, profits,...
09-01 22:25
美股大行评级 | 首予买入！Jersey Mike's获13家大行评级；大摩、富国银行齐上调迈威尔科技目标价，最高升至310美元
今日重点评级关注：Truist Securities：维持CoreWeave"买入"评级，目标价从155美元升至165美元；百德：维持亚德诺"跑赢大市"评级，目标价从450美元升至675美元
08-25 11:47
Morgan Stanley Initiates Coverage On Q32 Bio with Overweight Rating, Announces Price Target of $34
Morgan Stanley analyst Judah Frommer initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Overweight rating and announces Price Target of $34.
08-24 18:17
Q32 Bio Q2 EPS $(0.44) Beats $(0.54) Estimate
Q32 Bio (NASDAQ:QTTB) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.54) by 18.52 percent. This is a 43.59 percent increase over losses of $(0.78) per share from the same period last year.
08-05 19:21
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
Twilio To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird raised the price target for Kforce Inc (NASDAQ:KFRC) from $42 to $63. Baird analyst Mark Marcon maintain...
07-28 20:19
HC Wainwright & Co. Maintains Buy on Q32 Bio, Raises Price Target to $36
HC Wainwright & Co. analyst Joseph Pantginis maintains Q32 Bio (NASDAQ:QTTB) with a Buy and raises the price target from $13 to $36.
07-28 18:05
